Cargando…
Broken drug markets in infectious diseases: Opportunities outside the private sector?
A subset of anti-infective drugs are increasingly unavailable for patients in the United States due to pricing or withdrawal from the market. Timely market solutions are needed. We assert that solutions to ensure access to some essential anti-infective agents lie outside capital markets and that pub...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459471/ https://www.ncbi.nlm.nih.gov/pubmed/30973876 http://dx.doi.org/10.1371/journal.pntd.0007190 |
_version_ | 1783410182804471808 |
---|---|
author | Alpern, Jonathan D. Dunlop, Stephen J. Stauffer, William M. |
author_facet | Alpern, Jonathan D. Dunlop, Stephen J. Stauffer, William M. |
author_sort | Alpern, Jonathan D. |
collection | PubMed |
description | A subset of anti-infective drugs are increasingly unavailable for patients in the United States due to pricing or withdrawal from the market. Timely market solutions are needed. We assert that solutions to ensure access to some essential anti-infective agents lie outside capital markets and that public-private partnerships may be the most viable solution. |
format | Online Article Text |
id | pubmed-6459471 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-64594712019-05-03 Broken drug markets in infectious diseases: Opportunities outside the private sector? Alpern, Jonathan D. Dunlop, Stephen J. Stauffer, William M. PLoS Negl Trop Dis Viewpoints A subset of anti-infective drugs are increasingly unavailable for patients in the United States due to pricing or withdrawal from the market. Timely market solutions are needed. We assert that solutions to ensure access to some essential anti-infective agents lie outside capital markets and that public-private partnerships may be the most viable solution. Public Library of Science 2019-04-11 /pmc/articles/PMC6459471/ /pubmed/30973876 http://dx.doi.org/10.1371/journal.pntd.0007190 Text en © 2019 Alpern et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Viewpoints Alpern, Jonathan D. Dunlop, Stephen J. Stauffer, William M. Broken drug markets in infectious diseases: Opportunities outside the private sector? |
title | Broken drug markets in infectious diseases: Opportunities outside the private sector? |
title_full | Broken drug markets in infectious diseases: Opportunities outside the private sector? |
title_fullStr | Broken drug markets in infectious diseases: Opportunities outside the private sector? |
title_full_unstemmed | Broken drug markets in infectious diseases: Opportunities outside the private sector? |
title_short | Broken drug markets in infectious diseases: Opportunities outside the private sector? |
title_sort | broken drug markets in infectious diseases: opportunities outside the private sector? |
topic | Viewpoints |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459471/ https://www.ncbi.nlm.nih.gov/pubmed/30973876 http://dx.doi.org/10.1371/journal.pntd.0007190 |
work_keys_str_mv | AT alpernjonathand brokendrugmarketsininfectiousdiseasesopportunitiesoutsidetheprivatesector AT dunlopstephenj brokendrugmarketsininfectiousdiseasesopportunitiesoutsidetheprivatesector AT staufferwilliamm brokendrugmarketsininfectiousdiseasesopportunitiesoutsidetheprivatesector |